Exosome‑encapsulated microRNA‑223‑3p as a minimally invasive biomarker for the early detection of invasive breast cancer

Yoshikawa,Mio; Iinuma,Hisae; Umemoto,Yasuko; Yanagisawa,Takako; Matsumoto,Akiko; Jinno,Hiromitsu

doi:10.3892/ol.2018.8457

Exosome‑encapsulated microRNA‑223‑3p as a minimally invasive biomarker for the early detection of invasive breast cancer

Authors:
- Mio Yoshikawa
- Hisae Iinuma
- Yasuko Umemoto
- Takako Yanagisawa
- Akiko Matsumoto
- Hiromitsu Jinno
View Affiliations

Affiliations: Department of Surgery, Teikyo University School of Medicine, Tokyo 173‑0003, Japan
Published online on: April 10, 2018 https://doi.org/10.3892/ol.2018.8457
Pages: 9584-9592

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients diagnosed preoperatively with ductal carcinoma in situ (DCIS) breast cancer have the potential to develop invasive ductal carcinoma (IDC). The present study investigated the usefulness of exosome‑encapsulated microRNA‑223‑3p (miR‑223‑3p) as a biomarker for detecting IDC in patients initially diagnosed with DCIS by biopsy. The potential association between miR‑223‑3p and clinicopathological characteristics was examined in patients with breast cancer. Exosomes of 185 patients with breast cancer were separated from plasma by ultracentrifugation. Initially a microRNA (miRNA) microarray was examined to reveal the invasion specific miRNAs using exosomes collected from 6 patients with breast cancer, including 3 DCIS patients, 3 IDC patients and 3 healthy controls. In the miR microarray analysis the miR‑223‑3p levels of IDC patients demonstrated the highest fold‑change compared with those in the DCIS patients and healthy controls. The potential of miR‑223‑3p for cell proliferation and cell invasion were examined in vitro using MCF7 cells transfected with the miR‑223‑3p gene. MCF7 cells transfected with the miR‑223‑3p gene significantly promoted cell proliferation and cell invasive ability (P<0.05). The plasma exosomal miR‑223‑3p levels of the other 179 patients with breast cancer and 20 healthy controls were measured using TaqMan miR assays. The exosomal miR‑223‑3p levels of the patients with breast cancer were significantly increased compared with the healthy controls (P<0.01). A statistically significant association was observed between the exosomal miR‑223‑3p levels and histological type, pT stage, pN stage, pathological stage, lymphatic invasion and nuclear grade (P<0.05). The exosomal miR‑223‑3p levels of IDC patients (stage I) and upstaged IDC patients (stage I) were significantly higher compared with the DCIS patients (P<0.05). These results suggest that exosomal miR‑223‑3p may be a useful preoperative biomarker to identify the invasive lesions of DCIS patients diagnosed by biopsy. In addition, plasma exosome‑encapsulated miR‑223‑3p level was significantly associated with the malignancy of breast cancer.

View Figures

View References

1	The Editorial Board of the Cancer Statistics in Japan: Cancer Statistics in Japan 2015Foundation for Promotion of Cancer Research. National Cancer Center; Tokyo: 2016, https://ganjoho.jp/data/reg_stat/statistics/brochure/2015/cancer_statistics_2015.pdfMarch 30–2016
2	Welch HG, Prorok PC, O'Malley AJ and Kramer BS: Breast-cancer tumor size, overdiagnosis and mammography screening effectiveness. N Engl J Med. 375:1438–1447. 2016. View Article : Google Scholar : PubMed/NCBI
3	Fentiman IS: The dilemma of in situ carcinoma of the breast. Int J Clin Pract. 55:680–683. 2001.PubMed/NCBI
4	Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, Hutson L, Peltz E, Whitehead G, Reintgen D and Cantor A: Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg. 67:513–519. 2001.PubMed/NCBI
5	Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P and Houssami N: Ductal carcinoma in situ at core needle biopsy: Meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 260:119–128. 2011. View Article : Google Scholar : PubMed/NCBI
6	Grady WM and Tewai M: The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut. 59:706–708. 2010. View Article : Google Scholar : PubMed/NCBI
7	Graveel CR, Calderone HM, Westerhuis JJ, Winn ME and Sempere LF: Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press). 7:59–79. 2015.PubMed/NCBI
8	Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shiizu C, et al: Novel combination of serum microRNA for detedting brest cnacer in the early stage. Cancer Sci. 107:326–334. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ge Q, Zhou Y, Lu J, Bai Y, Xie X and Lu Z: miRNA in plasma exosome is stable under different storage conditions. Molecules. 19:1567–1575. 2014. View Article : Google Scholar
10	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
11	Simons M and Raposo G: Exosomes-vesicular carriers for intercelluar communication. Curr Opin Cell Biol. 21:575–581. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hannafon BN and Ding WQ: Intercelluar communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 14:14240–14269. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, et al: Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
14	Joyce DP, Kerin MJ and Dwyer RM: Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer. Int J Cancer. 139:1443–1448. 2016. View Article : Google Scholar : PubMed/NCBI
15	Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ: Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 18:902016. View Article : Google Scholar : PubMed/NCBI
16	Kurashige J, Hasegawa T, Niida A, Sugimachi K, Deng N, Mima K, Uchi R, Sawada G, Takahashi Y, Eguchi H, et al: Integrated molecular profiling of human gastric cancer identifies DDR2 as a potential regulator of peritoneal dissemination. Sci Rep. 6:223712016. View Article : Google Scholar : PubMed/NCBI
17	Dejima H, Iinuma H, Kanaoka R, Matsutani N and Kawamura K: Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 13:1256–1263. 2017. View Article : Google Scholar : PubMed/NCBI
18	Tsukamoto M, Iinuma H, Yagi T, Matsuda K and Hashiguchi Y: Circulating exosomal MicroRNA-21 as a biomarker in each tumor stage of colorectal cancer. Oncology. 92:360–370. 2017. View Article : Google Scholar : PubMed/NCBI
19	Bombonati A and Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 223:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
20	Osako T, Iwase T, Ushijima M, Horii R, Fukami Y, Kimura K, Matsuura M and Akiyama F: Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ. Cancer Sci. 105:576–582. 2014. View Article : Google Scholar : PubMed/NCBI
21	Chan MY and Lim S: Predictors of invasive breast cancer in ductal carcinoma in situ initially diagnosed by core biopsy. Asian J Surg. 33:76–82. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kim J, Han W, Lee JW, You JM, Shin HC, Ahn SK, Moon DG, Cho N, Moon WK, Park IA and Noh DY: Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast. 21:641–645. 2012. View Article : Google Scholar : PubMed/NCBI
23	Yoshikawa M: Sentinel node biopsy in patients diagnosed with ductal carcinoma in situ preoperatively. Japanese Soc Sentinel Node Navigation Surg. 18:452016.
24	Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS and Ditzel HJ: Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Mol Oncol. 8:874–883. 2014. View Article : Google Scholar : PubMed/NCBI
25	Huang L, Li F, Deng P and Hu C: MicroRNA-223 promotes tumor progression in lung cancer A549 cells via activation of the NF-κB signaling pathway. Oncol Res. 24:405–413. 2016. View Article : Google Scholar : PubMed/NCBI
26	Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
27	Pinatel EM, Orso F, Penna E, Cimino D, Elia AR, Circosta P, Dentelli P, Brizzi MF, Provero P and Tavern D: miR-223 is a coordinator of breast cancer progression as reveraled by bioinformatics predictions. PLoS One. 9:e848592014. View Article : Google Scholar : PubMed/NCBI
28	Sun X, Li Y, Zheng M, Zuo W and Zheng W: MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1. PLoS One. 11:e01627542016. View Article : Google Scholar : PubMed/NCBI